ZOLANTIDINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H27N3OS
Molecular Weight	381.534
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C(CNC1=NC2=C(S1)C=CC=C2)COC3=CC=CC(CN4CCCCC4)=C3

InChI

InChIKey=KUBONGDXTUOOLM-UHFFFAOYSA-N

InChI=1S/C22H27N3OS/c1-4-13-25(14-5-1)17-18-8-6-9-19(16-18)26-15-7-12-23-22-24-20-10-2-3-11-21(20)27-22/h2-3,6,8-11,16H,1,4-5,7,12-15,17H2,(H,23,24)

HIDE SMILES / InChI

Molecular Formula	C22H27N3OS
Molecular Weight	381.534
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2894879 | https://www.ncbi.nlm.nih.gov/pubmed/29162912 | https://www.ncbi.nlm.nih.gov/pubmed/24530460 | https://www.ncbi.nlm.nih.gov/pubmed/15140633

Zolantidine is the novel benzthiazole derivative. It is a centrally acting potent antagonist of histamine at H2-receptors. It was found to be a competitive inhibitor of the histamine catabolising enzyme in brain, histamine N-methyltransferase. High aggression in histamine N-methyltransferase knockout mice was suppressed by treatment with zolantidine, indicating that abnormal histamine H2 receptor activation promoted aggression in knockout mice. Histamine H(3) receptor antagonist JNJ-10181457-induced anxiety-like behaviours were dominantly reduced by zolantidine. Zolantidine significantly attenuated the discriminative stimulus effects of morphine.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Histamine H2 receptor 46 Target ID: CHEMBL4654 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2894879	Antagonist 2778	6.3 null [pKi]
Histamine N-methyltransferase 10 Target ID: Q9EST2 Gene ID: 1.00135536E8 Gene Symbol: HNMT Target Organism: Cavia porcellus (Guinea pig) Sources: https://www.ncbi.nlm.nih.gov/pubmed/2894879	Inhibitor 8297	6.6 null [pKi]
Histamine H1 receptor 315 Target ID: P31389 Gene ID: NA Gene Symbol: HRH1 Target Organism: Cavia porcellus (Guinea pig) Sources: https://www.ncbi.nlm.nih.gov/pubmed/2894879	Antagonist 2778	5.1 null [pKi]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Anxiety 267 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24530460	Primary		Preclinical	Unknown Approved Use Unknown
Cholestatic pruritus 2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19825905	Palliative		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Histamine H(3)-receptor antagonism improves memory retention and reverses the cognitive deficit induced by scopolamine in a two-trial place recognition task.	2001 Oct 15	11640976
Histamine H(2) -like receptors in chick cerebral cortex: effects on cyclic AMP synthesis and characterization by [(3) H]tiotidine binding.	2002 Jun	12065605
Enhanced antinociceptive effects of morphine in histamine H2 receptor gene knockout mice.	2006 Sep	16806305
Histamine N-methyltransferase regulates aggression and the sleep-wake cycle.	2017 Nov 21	29162912

Patents

Sample Use Guides

In Vivo Use Guide

10 mg/kg

Route of Administration: Intraperitoneal

In Vitro Use Guide

Zolantidine also inhibited histamine stimulated adenylate cyclase in a guinea-pig cardiac ventricle homogenate. An IC50 value of 840 ± 60 nM was obtained, corresponding to a Ki value of 52 ± 4 nM, (pKi 7.3).

Substance Class	Chemical Created by `admin` on `Fri Dec 15 18:12:12 UTC 2023` Edited by `admin` on `Fri Dec 15 18:12:12 UTC 2023`
Record UNII	M1108XAY01
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ZOLANTIDINE

Common Name

English

SKF-95282

Code

English

2-BENZOTHIAZOLAMINE, N-(3-(3-(1-PIPERIDINYLMETHYL)PHENOXY)PROPYL)-

Systematic Name

English

Code System Code Type Description

CAS

104076-38-2